CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/03/21
Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to DeclineZacks Investment Research • 10/20/21
Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More24/7 Wall Street • 10/19/21
3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will SkyrocketThe Motley Fool • 10/19/21
Crispr's stock is down 5% after sharing early-stage data for its CAR-T therapy candidateMarket Watch • 10/13/21
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignanciesGlobeNewsWire • 10/12/21
CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference Call TranscriptSeeking Alpha • 10/04/21